EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children

Eckard Hamelmann iD, Eva Hammerby iD, Katrine Skaarup Scharling, Mikkel Pedersen, Anna Okkels iD, Jochen Schmitt iD

Allergy · 2024-04 · 79 (4) · 1018-1027

DOI: 10.1111/all.15985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 26.12.2023. Verfasst von Eckard Hamelmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Children's Center Bethel, Bielefeld University, Bielefeld, Germany. Hauptthemen laut MEDLINE: Asthma, Rhinitis, Allergic, Rhinitis, Allergic, Seasonal, Sublingual Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ALK, Bøge Allé 1, 2970 Hørsholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic rhinitis (AR) is a chronic inflammatory disease of the upper airway, which progresses into allergic asthma (AA) in up to 45% of children. This analysis aimed to investigate clinical and economic benefits of sublingual allergen immunotherapy (SLIT tablets) initiated early in childhood for the treatment of AR by quantifying the long‐term reduction in new cases of AA.

Methods

A Markov model was developed to estimate the long‐term effects of SLIT tablets on the risk of developing asthma. Key parameters were primarily based on data from the GRAZAX® Asthma Prevention trial and included the age‐ and treatment‐dependent risk of developing AA as well as annual probabilities of progression/remission in AR severity. Healthcare costs were estimated using data from the REACT study.

Results

In a modelled cohort of children with moderate‐to‐severe seasonal AR initiated on SLIT tablets at ages 7 and 12, 24% and 29%, respectively, develop AA during a 20‐year period. In comparison, when initiated at age 5, 19% develop AA. Additionally, initiation of SLIT tablets at age 5 is associated with a total healthcare cost of EUR 20,429 per patient, whereas initiation at ages 7 and 12 is associated with, respectively, EUR 21,050 and EUR 22,379 per patient 20 years after AR diagnosis.

Conclusion

Initiation of SLIT tablets in early childhood is associated with a clinically meaningful and permanent reduction in new cases of AA and lower healthcare costs among children with AR. This finding supports the clinical relevance of initiating SLIT tablets early for children with AR to obtain long‐term clinical benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaRhinitis, AllergicRhinitis, Allergic, SeasonalSublingual ImmunotherapyChild, PreschoolHumansAllergensDesensitization, ImmunologicTabletsTreatment OutcomeClinical Trials as Topic

Stichwörter der Autor:innen

allergen immunotherapyallergic rhinitisasthmacost‐effectivenessprevention

Substanzen

AllergensTablets

Autor:innen und Institutionen

  • Children's Center Bethel, Bielefeld University, Bielefeld, Germany.
  • ALK, Hørsholm, Germany.
  • EY Godkendt Revisionspartnerselskab, Frederiksberg, Germany.
  • Center for Evidence-based Healthcare, TU Dresden, Dresden, Germany.

ORCID-Profile: Eckard Hamelmann, Eva Hammerby, Anna Okkels, Jochen Schmitt

Förderung

  • ALK, Bøge Allé 1, 2970 Hørsholm

Zitieren

APA

Hamelmann, E., Hammerby, E., Scharling, K. S., Pedersen, M., Okkels, A., & Schmitt, J. (2024). Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children. Allergy, 79(4), 1018-1027. https://doi.org/10.1111/all.15985

Vancouver

Hamelmann E, Hammerby E, Scharling KS, Pedersen M, Okkels A, Schmitt J. Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children. Allergy. 2024;79(4):1018-1027. doi:10.1111/all.15985

BibTeX
@article{Hamelmann2024,
  author = {Hamelmann, Eckard and Hammerby, Eva and Scharling, Katrine Skaarup and Pedersen, Mikkel and Okkels, Anna and Schmitt, Jochen},
  title = {Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {4},
  pages = {1018--1027},
  doi = {10.1111/all.15985}
}
Kostenlos starten →